The front-line therapy of macular edema associated with diabetic retinopathy or retinal vascular occlusions is anti-VEGF therapy, delivered into the eye by intravitreal injection and sometimes augmented with intravitreal corticosteroid and/or retinal laser photocoagulation (24–26). The gene discussed is VEGFA; the disease is retinal vascular occlusion.